Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's Lymphoma Ascites tumor in mice

Clinica Chimica Acta

Volumn 366, Issue 1-2, 2006, Pages 322-328

  Ajith, T A ^a   Harikumar, K B ^b   Thasna, H ^a   Sabu, M C ^b   Babitha, N V ^c  

^a AMALA INSTITUTE OF MEDICAL SCIENCES   (India)

^b AMALA CANCER RESEARCH CENTRE   (India)

^c St Alosius HSS   (India)

Author keywords

Antitumor; Chemoprevention; Cytotoxicity; Lipid peroxidation; Lovastatin; Proapoptotic

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FERROUS ASCORBATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSTATIN; MEVINOLIN; TRYPAN BLUE;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES TUMOR; ASCITES TUMOR CELL; CANCER INHIBITION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DNA DAMAGE; DNA DETERMINATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; GIEMSA STAIN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; LIVER HOMOGENATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID PEROXIDATION; LOVASTATIN; LYMPHOMA; MALE; MICE; NEOPLASM TRANSPLANTATION; SURVIVAL ANALYSIS;

ANIMALIA;

EID: 33644693329     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.11.012     Document Type: Article

References (45)

1. R.J. Scheuplein Perspectives on toxicological risk-an example: food borne carcinogenic risk Crit Rev Food Sci Nutr 32 1992 105 121
2. B.S. Appleton, and R.E. Landers Oil gavage effects in tumor incidence in the national toxicology programmers two year carcinogenesis bio assay Adv Exp Med Biol 206 1985 99 103
3. B. Armstrong, and R. Doll Environmental factor and cancer incidence and mortality in different countries, with special reference to dietary practice Int J Cancer 15 1975 617 621
4. J.M. Martin-Moreno, and W.L. Gorgojo Dietary fat, olive oil intake and breast cancer risk Int J Cancer 58 1994 774
5. A. Trichopoilon, K. Katsouyanni, and S. Stuver Consumption of olive oil and specific food groups in relation to breast cancer risk in Greece J Natl Cancer Inst 87 1995 110
6. H. Kasai Analysis of formation of oxidative DNA damage 8-hydroxy-2 deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis Mutat Res 387 1997 147 163
7. K. Vzunk, H. Vural, T. Ozturk, F. Ozer, and I. Imecik Diagnostic value of lipid peroxidation in lung cancer East J Med 5 2000 48 51
8. S. Petruzzelli, E. Hietameu, and H. Bartsch Lipid peroxidation in cigarette smokers and lung cancer patients Chest 98 1990 930 935
9. S.Y. Sun, N. Hail, and J.R. Lotan Apoptosis as a novel target for cancer chemoprevention J Natl Cancer Inst 96 2004 662 672
10. S.J. Lee, M.J. Ha, and J. Lee Inhibition of the 3-hydroxy-3 methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells J Biol Chem 273 1998 10618 10623
11. A. Giacosa, R. Filiberti, M.J. Hill, and J. Faivre Vitamins and cancer chemoprevention Eur J Cancer Prev 6 1997 S47 S54
12. J. Shephrd The statin era in search of the ideal lipid regulating agent Heart 85 2001 259 264
13. C. Lintott, R. Scott, W. Sutherland, and J. Bremer Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin Aust NZ J Med 23 1993 381 386
14. R.H. Knopp Drug treats of lipid disorders N Engl J Med 341 1999 498 511
15. M. Jakobisilak, and J. Golab Potential antitumor effects of statins (review) Int J Oncol 23 2003 1055 1069
16. M.A. Shibata Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models Carcinogenesis 24 2003 453 459
17. H. Ohkawa, N. Ohishi, and K. Yagi Assay for lipid peroxidation in animal tissues by thiobarbuturic acid reaction Anal Biochem 95 1979 351 355
18. T.A. Ajith, and K.K. Janardhanan Cytotoxic and antitumor activities of a polypore macrofungus, Phellinus rimosus (Berk) Pilat J Ethnopharmacol 84 2003 157 162
19. J.D. Jiang, Y. Wang, J. Roboz, J. Strauchen, J.F. Holland, and J.G. Bekesi Inhibition of microtubule assembly in tumor cells by 3-bromoacetylamine benzoylurea, a new cancericidal compound Cancer Res 58 1998 2126 2135
20. C.L. Kuo, C.C. Chou, and B.Y.M. Yung Berberine complexes with DNA in the berberine induced apoptosis in human leukemic HL-60 cells Cancer Lett 93 1995 193 200
21. W.K. Hong, and M.B. Sporn Recent advances in chemoprevention of cancer Science 278 1997 1073 1077
22. L.W. Wattenberg What are the critical attributes for cancer chemopreventive agents? Ann N Y Acad Sci 768 1995 73 81
23. D.J. Kornbrust, J.S. MacDonald, and C.P. Peter Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits J Pharmacol Exp Ther 248 1989 498 505
24. D.F. Alonso, H.G. Farina, G. Skilton, M.R. Gabri, M.S. De Lorenzo, and D.E. Gomez Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis Breast Cancer Res Treat 50 1998 83 93
25. M. Zornig, A.O. Hueber, W. Baum, and G. Evan Apoptosis regulators and their role in tumorigenesis Biochim Biophys Acta 1551 2001 F1 F37
26. P. Costantini, E. Jocotot, D. Decandin, and G. Kroemer Mitochondrion as a novel target of anticancer chemotherapy J Natl Cancer Inst 92 2000 1042 1053
27. J.C. Reed Apoptosis-targeted therapies for cancer Cancer Cell 3 2002 17 22
28. Z. Xia, M.M. Tan, W.W. Wong, J. Dimitroulakos, M.D. Minden, and L.Z. Penn Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells Leukemia (Baltimore) 15 2001 1398 1407
29. J. Wu, W.W. Wong, F. Khosravi, M.D. Minden, and L.Z. Penn Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis Cancer Res 64 2004 6461 6468
30. M. Marcelli, G.R. Cunningham, and S.J. Haidacher Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP Cancer Res 58 1998 76 83
31. K.Z. Guyton, and T.W. Kesler Oxidative mechanism in carcinogesis Br Med Bull 49 1993 523 526
32. L.J. Marnett, and M.A. Tuttle Comparison of the mutagenecity of MDA and the side products formed during its chemical synthesis Cancer Res 40 1980 276 279
33. D. Hristozov, V. Gadjeva, T. Vlaykova, and G. Dimitrov Evaluation of oxidative stress in patients with cancer Arch Physiol Biochem 109 2001 331 336
34. G. Ray, S. Batra, and N.K. Shukla Lipid peroxidation, free radical production and antioxidant status in breast cancer Breast Cancer Res Treat 59 2000 163 170
35. H. Bartsch, and J. Nair Potential role of lipid peroxidation-derived DNA damage in human colon carcinogenesis: studies on exocyclic base adducts as stable oxidative stress marker Cancer Detect Prev 26 2002 4737 4740
36. R.A. Floyd The role of 8-hydroxyguanine in carcinogenesis Carcinogenesis 11 1990 1447 1450
37. F. Franzoni, A. Quiñones-Galvan, F. Regoli, E. Ferrannini, and F. Galeta A comparative study of the in vitro antioxidant activity of statins Int J Cardiol 90 2003 233 237
38. J. Beltowski Statins and modulation of oxidative stress Toxicol Mech Methods 15 2005 61 92
39. M. Suffness, and J.M. Pezzuto Assays related to cancer drug discovery M. Suffness J.M. Pezzuto Methods in plant biochemistry 1991 Academic Press New York 71 110
40. P. Prasanna, A. Thibault, L. Liu, and D. Samid Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells J Neurochem 66 1996 710 716
41. C. Denoyelle, M. Vasse, and M. Korner Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study Carcinogenesis (Lond) 22 2001 1139 1148
42. A. Wachtershauser, B. Akoglu, and J. Stein HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2 Carcinogenesis (Lond) 22 2001 1061 1067
43. H.L. Bouterfa, V. Sattelmeyer, S. Czub, D. Vordermark, K. Roosen, and J.C. Tonn Inhibition of Ras farnesylation by lovastatin leads to down-regulation of proliferation and migrating in primary cultured human gliblastoma cells Anticancer Res 20 2000 2761 2771
44. A. Thibault, D. Samid, and A.C. Tompkins Phase I study of lovastatin, an inhibitor of the mevalonate pathway in patients with cancer Clin Cancer Res 2 1996 483 491
45. J. Larner, J. Jane, E. Laws, R. Packer, C. Myers, and M. Shaffrey A Phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme Am J Clin Oncol 21 1998 579 583